Deciphera Pharmaceuticals Inc
NASDAQ:DCPH
Deciphera Pharmaceuticals Inc
NASDAQ:DCPH
Price:
25.47 USD
0.04%
Market Closed
Updated:
May 21, 2024
Deciphera Pharmaceuticals Inc
Cost of Revenue
|
Deciphera Pharmaceuticals Inc
Cost of Revenue Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Deciphera Pharmaceuticals Inc
NASDAQ:DCPH
|
Cost of Revenue
-$5.3m
|
CAGR 3-Years
-128%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cost of Revenue
-$18.3B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cost of Revenue
-$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cost of Revenue
-$9.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cost of Revenue
-$1.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
-29%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cost of Revenue
-$1.8B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-27%
|
See Also
What is Deciphera Pharmaceuticals Inc's Cost of Revenue?
Cost of Revenue
-5.3m
USD
-5.3m
USD
Based on the financial report for Mar 31, 2024, Deciphera Pharmaceuticals Inc's Cost of Revenue amounts to -5.3m USD.
What is Deciphera Pharmaceuticals Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-128%
-128%
Over the last year, the Cost of Revenue growth was 40%. The average annual Cost of Revenue growth rates for Deciphera Pharmaceuticals Inc have been -128% over the past three years .
You don't have any saved screeners yet
